PATENT Docket No. 275.0010 0101

Applicant(s): MUNN et al. Serial No.: 10/780,797 Confirmation No.:1508 PECEIVED CENTRAL FAX CENTER APR 1 4 2008 PECEIVED CENTRAL FAX CENTER APR 1 4 2008 PERMITTED STATES PATENT AND TRADEMARK OFFICE PECEIVED CENTRAL FAX CENTER APR 1 4 2008 PERMITTED STATES PATENT AND TRADEMARK OFFICE PECEIVED CENTRAL FAX CENTER APR 1 4 2008 PERMITTED STATES PATENT AND TRADEMARK OFFICE PECEIVED CENTRAL FAX CENTER APR 1 4 2008 PERMITTED STATES PATENT AND TRADEMARK OFFICE APR 1 4 2008 PERMITTED STATES PATENT AND TRADEMARK OFFICE APR 1 4 2008 PERMITTED STATES PATENT AND TRADEMARK OFFICE APR 1 4 2008 PERMITTED STATES PATENT AND TRADEMARK OFFICE APR 1 4 2008

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

COMBINATION WITH OTHER THERAPEUTIC MODALITIES

USE OF INHIBITORS OF INDOLEAMINE-2, 3-DIOXYGENASE IN

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

For:

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with C.F.R. §§ 1.97 et. seq., the materials enclosed herewith are brought to the attention of the Examiner as possibly being of interest in connection with the above-identified patent application. Per M.P.E.P. § 609, the information cited in the present Information Disclosure Statement shall not be construed to be an admission that the information is, or is considered to be, material to patentability. Consideration of each of the documents listed on the attached 1449 form is respectfully requested. Pursuant to the provisions of M.P.E.P. §609, Applicants further request that a copy of the 1449 form, marked as being considered and initialed by the Examiner, be returned with the next Official Communication.

Since this Information Disclosure Statement is submitted after the receipt of an Office Action in the above-identified patent application, Applicants hereby authorize a charge of \$180 to Deposit Account No. 13-4895 to cover the fee required under 37 C.F.R. §§1.97(c) and 1.17(p). Please charge any additional fees or credit any overpayment to Deposit Account No. 13-4895.

04/15/2008 HMARZII 00000056 134895 10780797 01 FC:1806 180.00 DA

Page 2 of 2

RECEIVED
CENTRAL FAX CENTER

APR 1 4 2008

Supplemental Informatin Disclosure Statement Serial No. 10/780,797 Filed: February 17, 2004

USE OF INHIBITORS OF INDOLEAMINE-2, 3-DIOXYGENASE IN COMBINATION WITH OTHER

THERAPEUTIC MODALITIES

The Examiner is invited to contact Applicants' Representatives at the telephone number listed below if they can be of any assistance during prosecution of the present application.

CERTIFICATE UNDER 37 C.F.R. 1.8:

The undersigned hereby certifies that this paper is being transmitted by facsimile in accordance with 37 CFR §1.6(d) to the Patent and Trademark Office, addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA

22313-1450, on this 14 day of 1971, 2008 at 11:40 A.M. (Central Time).

By: Sandy Druhatt

April 14, 2008

Date

Respectfully submitted

By

Mueting, Raasch & Gebhardt, P.A.

P.O. Box 581415

Minneapolis, MN 55458-1415

Phone: (612)305-1220 Facsimile: (612)305-1228 Customer Number 26813

Nancy A. Johnson

Reg. No. 47,266

Direct Dial (612)305-4723